Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mw150
- Development stage
- Phase 2
- Lead developer
- Neurokine Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MW150 is a novel, CNS-penetrant, orally active small molecule inhibitor that selectively targets p38α mitogen-activated protein kinase (MAPK14). It was custom-designed to modulate neuroinflammation and neuronal dysfunction by inhibiting the phosphorylation activity of p38α MAPK in activated glia. Preclinical studies have shown efficacy in both preventive and disease-stage therapeutic paradigms for Alzheimer's disease and other dementias. MW150 is being developed as a potential disease-modifying therapy for neurodegenerative diseases with unmet needs. Its mechanism of action is distinct from current approved or late-stage drugs for Alzheimer's disease[1][2][3][4].
- Other names
- MW150MW-150MW 150
02
Targets
MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on mw150.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mw150.